Evidence map›Paper›PMID 33466806›Full record

ArticleMolecules (Basel, Switzerland)2021

New Anti-Leukemic Effect of Carvacrol and Thymol Combination through Synergistic Induction of Different Cell Death Pathways.

Fatima Bouhtit, Mehdi Najar, Douâa Moussa Agha, Rahma Melki, Mustapha Najimi, Khalid Sadki, Noureddine Boukhatem, Dominique Bron, Nathalie Meuleman, Abdellah Hamal and 3 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Antitumor effects of volatile components ofFrontiers in oncology · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Monoterpenoid synergy: a new frontier in biological applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  8. Therapeutic effects ofFrontiers in pharmacology · 2025
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. The Synergistic Effect ofDrug design, development and therapy · 2021
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Fatima BouhtitLaboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium.
Mehdi NajarGenetics and Immune Cell Therapy Unit, LBBES Laboratory, Faculty of Sciences, University Mohammed Premier, Oujda 60000, Morocco.ORCID 0000-0002-9740-9122
Douâa Moussa AghaLaboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium.
Rahma MelkiGenetics and Immune Cell Therapy Unit, LBBES Laboratory, Faculty of Sciences, University Mohammed Premier, Oujda 60000, Morocco.
Mustapha NajimiLaboratory of Pediatric Hepatology and Cell Therapy, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium.ORCID 0000-0002-7329-9635
Khalid SadkiLaboratory of Human Pathologies Biology, Faculty of Sciences, Mohammed V University, Rabat, Agdal-Rabat 10090, Morocco.
Noureddine BoukhatemGenetics and Immune Cell Therapy Unit, LBBES Laboratory, Faculty of Sciences, University Mohammed Premier, Oujda 60000, Morocco.
Dominique BronLaboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium.
Nathalie MeulemanLaboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium.
Abdellah HamalGenetics and Immune Cell Therapy Unit, LBBES Laboratory, Faculty of Sciences, University Mohammed Premier, Oujda 60000, Morocco.
Laurence LagneauxLaboratory of Clinical Cell Therapy, Jules Bordet Institute, Université Libre de Bruxelles, 1070 Brussels, Belgium.
Philippe LewalleLaboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium.
Makram MerimiLaboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium.
Université Libre de Bruxelles · BEMohamed I University · MAMohammed V University · MAUCLouvain · BE

Funding

L'Agence Nationale des Plantes Médicinales et Aromatiques (ANPMA) naLe Centre National pour la Recherche Scientifique et Technique (CNRST) naLes Amis de l'Institut Jules Bordet na
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is a cancer of the myeloid lineage of blood cells, and treatment for AML is lengthy and can be very expensive. Medicinal plants and their bioactive molecules are potential candidates for improving human health. In this work, we studied the effect of

Indexed as

ApoptosisAnti-Infective AgentsAntineoplastic AgentsCell ProliferationCymenesDrug SynergismHumansLeukemia, Myeloid, AcuteThymolTumor Cells, CulturedAnti-Infective AgentsAntineoplastic AgentscarvacrolCymenesThymolAML-cancer therapyapoptotic and non-apoptotic pathwaysbioactive moleculescell deathdrug combination-synergy

Identifiers

PMID33466806
PMCPMC7829697
OpenAlexW3119384085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.